Notification Date: 21 January 2026 Authority: Central Drugs Standard Control Organization Introduction Ministry of Health & Family Welfare Proposes Amendment to Drug Labelling Requirements In a significant regulatory development aimed at strengthening antimicrobial stewardship in India, the Ministry of Health and Family Welfare (MoHFW) has released a draft amendment to the Drugs Rules, 1945, proposing a new labelling requirement for antimicrobial drugs and their formulations. The draft notification, published under G.S.R. 51(E), seeks to introduce a distinctive visual identification system for antimicrobial products marketed in India. What is the Proposed Change? Under the proposed amendment to Rule 96 of the Drugs Rules, 1945, all antimicrobial drugs and their preparations will be required to display: A conspicuous blue vertical strip on the left side of the label extending throughout the body of the label, without affecting any other mandatory labelling information. This requirement will apply to antimicrobial products across various dosage forms and therapeutic categories. Why is this Amendment Important? Antimicrobial resistance (AMR) continues to be one of the most pressing global public health concerns. The proposed blue strip labelling is expected to: • Facilitate quick identification of antimicrobial medicines by healthcare professionals and pharmacists. • Promote rational prescribing and dispensing practices. • Enhance awareness among patients regarding the responsible use of antibiotics. • Support national and global antimicrobial stewardship initiatives. • Strengthen regulatory measures aimed at combating antimicrobial resistance. Impact on Pharmaceutical Manufacturers Once the amendment is finalized and notified, pharmaceutical manufacturers will need to undertake several compliance activities, including: • Revision of packaging artwork and label designs. • Regulatory review and approval of updated packaging materials. • Management of existing packaging inventories. • Coordination with printing and packaging vendors. • Timely implementation across all antimicrobial product portfolios. Companies involved in contract manufacturing, third-party manufacturing, and export-oriented operations should proactively assess the impact of the proposed changes on their packaging systems and compliance timelines. Industry Recommendation Although the amendment is currently in the draft stage, pharmaceutical companies are advised to begin evaluating their antimicrobial product portfolio and packaging infrastructure. Early planning can help minimize implementation challenges and ensure seamless regulatory compliance once the final notification is issued. Conclusion The proposed introduction of a blue identification strip for antimicrobial medicines represents another important step towards strengthening India's efforts to combat antimicrobial resistance. Pharmaceutical manufacturers should closely monitor further developments and prepare for potential implementation requirements that may arise upon final notification of the amendment. Our regulatory consulting team will continue to monitor updates from the Ministry of Health & Family Welfare and provide timely guidance to pharmaceutical manufacturers regarding compliance and implementation strategies. Tags: # CDSCO, # Antimicrobial Drugs, # Drug Labelling, # CDSCO Regulatory Update, # Ministry of Health and Family Welfare, # Pharma Industry News https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTM4Mjg=
We hate spam too.
